Integrating Genomic, eQTL, and Mendelian Randomization Analyses to Identify Microglial Drug Targets in Multiple Sclerosis
Journal of Cellular and Molecular Medicine · 2025-11 · 29 (22)
DOI: 10.1111/jcmm.70754 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 14.11.2025. Verfasst von Wu Yan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, First Affiliated Hospital of Kunming Medical University, Kunming, P. R. China. Hauptthemen laut MEDLINE: Mendelian Randomization Analysis, Multiple Sclerosis, Microglia, Quantitative Trait Loci. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Yunnan Fundamental Research Kunming Medical University Projects, Yunnan Clinical Center for Neurological and Cardiovascular Diseases, Yunnan Clinical Research Center for Neurological Disease.
Abstract (Originalsprache)
Multiple sclerosis (MS) is an autoimmune disease characterised by neuroinflammation and neurodegeneration. This study investigates genetic and immunological factors in MS, focusing on microglial regulation. We analysed differentially expressed genes using RNA sequencing from MS lesions (GSE108000) and plaques (GSE227781), validated with cis‐eQTL analysis, and integrated Mendelian randomisation (MR), SMR, co‐localisation, methylation, and protein–protein interaction (PPI) analyses to assess causal effects on MS risk. We identified five genes—ARHGAP25, HLA‐DRB1, MERTK, MS4A6A, and SYK—linked to MS susceptibility. MR revealed that elevated levels of ARHGAP25 (OR = 1.45), HLA‐DRB1 (OR = 2.24), MERTK (OR = 1.10), MS4A6A (OR = 1.15), and SYK (OR = 1.13) increased MS risk. SMR confirmed a causal link between HLA‐DRB1 and MS, while co‐localisation analysis showed shared variants with MS for HLA‐DRB1 (100%) and SYK (97.93%). Methylation analysis highlighted 10 sites within HLA‐DRB1, and PPI and DrugBank analyses revealed interactions between these genes and multiple proteins or chemicals. This study demonstrates the value of integrating genomic and eQTL data through MR to identify novel MS therapeutic targets, particularly microglial genes, offering potential new avenues for treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, First Affiliated Hospital of Kunming Medical University, Kunming, P. R. China.
ORCID-Profile: Wu Yan
Förderung
- Yunnan Fundamental Research Kunming Medical University Projects
- Yunnan Clinical Center for Neurological and Cardiovascular Diseases
- Yunnan Clinical Research Center for Neurological Disease
Zitieren
APA
Yan, W., Wen, J., & Jianhong, W. (2025). Integrating Genomic, eQTL, and Mendelian Randomization Analyses to Identify Microglial Drug Targets in Multiple Sclerosis. Journal of Cellular and Molecular Medicine, 29(22). https://doi.org/10.1111/jcmm.70754
Vancouver
Yan W, Wen J, Jianhong W. Integrating Genomic, eQTL, and Mendelian Randomization Analyses to Identify Microglial Drug Targets in Multiple Sclerosis. Journal of Cellular and Molecular Medicine. 2025;29(22). doi:10.1111/jcmm.70754
BibTeX
@article{Yan2025,
author = {Yan, Wu and Wen, Jiang and Jianhong, Wang},
title = {Integrating Genomic, eQTL, and Mendelian Randomization Analyses to Identify Microglial Drug Targets in Multiple Sclerosis},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
volume = {29},
number = {22},
doi = {10.1111/jcmm.70754}
}
EUVIMED